Abstract

In the past H2-receptor antagonist era, there was initially a lull as more and more ‘me-too’ drugs were developed. Then came the excitement of the proton pump inhibitors and the controversy of the pros and cons of moderate versus potent acid inhibition. The most recent explosion of knowledge has been in the discussion of pH versus Helicobacter pylori, but on the horizon is lurking the promise of the resurgence of the surgical option.